Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

29 Nov 2022

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

ターゲット市場の実像をつかむ

Multiple Myeloma Pricing, Reimbursement, and Access

14 Nov 2022

Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.

ターゲット市場の実像をつかむ

Acute Myeloid Leukemia Market Outlook Seminar

14 Nov 2022

There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.

ターゲット市場の実像をつかむ, Biomedtracker: 開発中医薬品をFDA承認確率...

2021 Post-ASCO Insights and Analysis

11 Aug 2021

The American Society of Clinical Oncology (ASCO) hosted its annual meeting from June 4-8 2021 and our team has the exclusive insights and analysis you can access today.

世界の薬事規制動向＆情報を配信

How Sustainable Is England's Cancer Drugs Fund?

27 Nov 2020

The Cancer Drugs Fund has improved access to oncology drugs, but if it is to remain fit for purpose it will need to evolve.

Breast Cancer Clinical Landscape and Recent Trends Whitepaper

27 Nov 2020

Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.